Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Short Interest Up 31.6% in March

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) saw a significant increase in short interest in March. As of March 13th, there was short interest totaling 427,713 shares, an increase of 31.6% from the February 26th total of 325,076 shares. Based on an average daily trading volume, of 220,622 shares, the short-interest ratio is presently 1.9 days. Currently, 0.8% of the company’s stock are short sold.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. Ikarian Capital LLC acquired a new position in shares of Damora Therapeutics, Inc. Common Stock during the fourth quarter worth approximately $6,574,000. Janus Henderson Group PLC acquired a new stake in shares of Damora Therapeutics, Inc. Common Stock in the fourth quarter worth $40,000. Boothbay Fund Management LLC bought a new position in Damora Therapeutics, Inc. Common Stock during the fourth quarter worth $2,204,000. Jain Global LLC bought a new position in Damora Therapeutics, Inc. Common Stock during the fourth quarter worth $2,774,000. Finally, Remedium Capital Partners LLC acquired a new position in Damora Therapeutics, Inc. Common Stock during the 4th quarter valued at $2,772,000. 14.20% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on DMRA shares. Leerink Partners assumed coverage on Damora Therapeutics, Inc. Common Stock in a research note on Wednesday, January 7th. They set an “outperform” rating and a $46.00 price target for the company. Zacks Research upgraded Damora Therapeutics, Inc. Common Stock to a “hold” rating in a report on Friday, January 9th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Damora Therapeutics, Inc. Common Stock in a research report on Monday, December 29th. Guggenheim reiterated a “buy” rating and set a $40.00 price target (up from $36.00) on shares of Damora Therapeutics, Inc. Common Stock in a report on Tuesday, February 17th. Finally, UBS Group started coverage on shares of Damora Therapeutics, Inc. Common Stock in a research report on Tuesday, February 17th. They issued a “buy” rating and a $45.00 price target on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, three have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Damora Therapeutics, Inc. Common Stock currently has an average rating of “Moderate Buy” and a consensus target price of $44.25.

Damora Therapeutics, Inc. Common Stock Stock Performance

Shares of Damora Therapeutics, Inc. Common Stock stock traded up $1.83 during trading on Tuesday, reaching $26.10. The company’s stock had a trading volume of 98,366 shares, compared to its average volume of 235,217. Damora Therapeutics, Inc. Common Stock has a one year low of $2.01 and a one year high of $38.33. The firm has a market cap of $1.57 billion, a price-to-earnings ratio of -2.16 and a beta of 1.42. The business’s fifty day moving average price is $27.00 and its 200-day moving average price is $20.04.

About Damora Therapeutics, Inc. Common Stock

Galecto Inc is a clinical‐stage biotechnology company developing small‐molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company’s research focuses on inhibiting galectin‐3, an extracellular carbohydrate‐binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase‐like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue.

Its lead programs include GB0139, an inhaled galectin‐3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin‐3 inhibitor being evaluated for systemic fibrotic disorders.